Results of the Phase III EAGLE study leave Merck’s Keytruda and Bristol’s Opdivo as the dominant players in the space of HNSCC after progression on platinum-based chemotherapy.
Article Source: Imfinzi looks flimsy in AstraZeneca’s Phase III head and neck cancer study.
0 Comments